Laxminarayan Bhat
2023
In 2023, Laxminarayan Bhat earned a total compensation of $2.8M as Chief Executive Officer and President at REVIVA PHARMACEUTICALS HOLDINGS, a 394% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $157,500 |
|---|---|
| Option Awards | $2,157,247 |
| Salary | $450,000 |
| Total | $2,764,747 |
Bhat received $2.2M in option awards, accounting for 78% of the total pay in 2023.
Bhat also received $157.5K in non-equity incentive plan and $450K in salary.
Rankings
In 2023, Laxminarayan Bhat's compensation ranked 338th out of 3,006 executives tracked by ExecPay. In other words, Bhat earned more than 88.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 338 out of 3,006 | 89th |
Division Manufacturing | 190 out of 1,650 | 89th |
Major group Chemicals And Allied Products | 130 out of 918 | 86th |
Industry group Drugs | 127 out of 881 | 86th |
Industry Pharmaceutical Preparations | 79 out of 637 | 88th |
Source: SEC filing on October 28, 2024.
Bhat's colleagues
We found one more compensation record of an executive who worked with Laxminarayan Bhat at REVIVA PHARMACEUTICALS HOLDINGS in 2023.
2023
Narayan Prabhu
REVIVA PHARMACEUTICALS HOLDINGS